期刊
JOURNAL FOR IMMUNOTHERAPY OF CANCER
卷 6, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s40425-018-0443-6
关键词
Immune check point inhibitors; Immune-related adverse events; Vasculitis
Commentary on << Ipilimumab induced vasculitis >> by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resected stage III B/C melanoma. We report a similar case of acral vasculitis occurring with a combination of anti-CTLA-4 (tremelimumab) and anti-PD-L1 (durvalumab) prescribed for the management of a metastatic urothelial bladder cancer. In contrast to Padda A. et al., we observed a significant improvement with oral corticosteroids.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据